Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
$0.89
$0.84
$0.00
▼
$1.80
$11.49M0.837,615 shs4,910 shs
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
$7.30
$7.30
$2.00
▼
$16.10
$11.72M1.185,025 shsN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$1.70
-9.6%		$2.46
$2.90
▼
$23.42
$11.70M1.4116,506 shs85,065 shs
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$0.50
+4.4%		$0.59
$0.44
▼
$2.14
$4.27M4.91918,008 shs331,480 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
0.00%-8.76%-31.13%+101.14%-41.00%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.00%0.00%0.00%0.00%-39.67%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
0.00%-11.92%-16.26%-56.63%-89.03%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
+4.39%-5.43%-11.81%-27.36%-66.59%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
$0.89
$0.84
$0.00
▼
$1.80
$11.49M0.837,615 shs4,910 shs
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
$7.30
$7.30
$2.00
▼
$16.10
$11.72M1.185,025 shsN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$1.70
-9.6%		$2.46
$2.90
▼
$23.42
$11.70M1.4116,506 shs85,065 shs
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$0.50
+4.4%		$0.59
$0.44
▼
$2.14
$4.27M4.91918,008 shs331,480 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
0.00%-8.76%-31.13%+101.14%-41.00%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.00%0.00%0.00%0.00%-39.67%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
0.00%-11.92%-16.26%-56.63%-89.03%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
+4.39%-5.43%-11.81%-27.36%-66.59%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
0.00
N/AN/AN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.00
N/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2.33
Hold$51.752,944.12% Upside
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest RDHL, PSTV, FNCH, and EGRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/6/2026
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
8/3/2026
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
(Data available from 10/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
$257.55M0.04$2.21 per share0.40N/A∞
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/A$14.25 per shareN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/AN/AN/AN/A$0.72 per shareN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$290K15.36N/AN/A$0.83 per share0.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
$35.64M$1.180.75N/AN/AN/AN/AN/A11/9/2026 (Estimated)
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
-$74.75M-$8.82N/AN/AN/AN/A-69.14%-26.92%N/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$22.39M-$2.30N/AN/AN/A-230.24%-198.48%-73.13%N/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
-$430KN/AN/AN/AN/AN/AN/AN/AN/A

Latest RDHL, PSTV, FNCH, and EGRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026N/A
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
$0.7330N/AN/AN/A$45.03 millionN/A
8/13/2026Q2 2026
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$0.88-$1.31-$0.43-$1.31$1.11 million$0.41 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
N/AN/AN/AN/AN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/AN/AN/AN/AN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
N/AN/AN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/A
3.87
3.87
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/A
2.27
2.27
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
N/A
0.34
N/A

Institutional Ownership

CompanyInstitutional Ownership
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
85.36%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
21.77%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
3.28%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
7.20%

Insider Ownership

CompanyInsider Ownership
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
28.90%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
44.90%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2.50%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
6.81%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
10012.99 million9.23 millionNo Data
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
1901.61 million885,000No Data
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
206.88 million6.71 millionNot Optionable
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
2108.89 million8.28 millionNo Data

Recent News About These Companies

$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma
October 19 at 8:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/2-9-million-nci-grant-awarded-for-clinical-development-of-redhills-opaganib-and-car-t-cell-combination-in-ultra-high-risk-multiple-myeloma-302912502.html
Redhill Biopharma (NASDAQ:RDHL) Stock Price Crosses Below 200 Day Moving Average - Should You Sell?
October 13, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31113588
RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results
September 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhill-biopharma-announces-operational-highlights-and-first-half-2026-financial-results-302894804.html
RedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties?
September 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/redhill-rdhl-acquires-rebyota-clenpiq-160630625.html
RedHill acquires rights to Ferring’s Rebyota and Clenpiq
September 1, 2026  |  thepharmaletter.comT
Redhill Biopharma stock doubles in one session — here's why
September 1, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/redhill-biopharma-stock-doubles-in-one-session-here-s-why/ar-AA2bhfIt
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®
September 1, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/currencies/redhill-announces-transformational-acquisition-of-commercialization-rights-to-ferring-s-rebyota-and-clenpiq-1036510879
RedHill divests Talicia business to Apotex
September 1, 2026  |  thepharmaletter.comT
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®
September 1, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhill-announces-transformational-acquisition-of-commercialization-rights-to-ferrings-rebyota-and-clenpiq-302866106.html
RedHill Biopharma Stock Surges 64% Over Deal To Divest Talicia Business
August 31, 2026  |  rttnews.comhttps://www.rttnews.com/3687115/redhill-biopharma-stock-surges-64-over-deal-to-divest-talicia-business.aspx
RedHill Biopharma (NASDAQ: RDHL) Soars to $1.60 - Monetizes Talicia Stake in $18 Million Cash Deal With Apotex
August 31, 2026  |  investorideas.comI
RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
August 31, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhill-divests-talicia-to-apotex-for-18-million-cash-upfront-plus-milestones-to-fuel-strategic-growth-opportunities-302864832.html
Redhill Biopharma Ltd (NASDAQ: RDHL) - Share Price and Research
August 8, 2026  |  intelligentinvestor.com.auI
Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development
July 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ebola-cases-and-deaths-rapidly-mount---redhill-updates-on-opaganib-emergency-outbreak-development-302836392.html
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
June 22, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhill-biopharma-announces-closing-of-up-to-19-4-million-private-placement-302806815.html
RedHill Biopharma announces up to $19.4M private placement
June 18, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/redhill-biopharma-announces-up-to-194m-private-placement/ar-AA25Xq2A
RedHill Biopharma Announces Up To $19.4 Million Private Placement
June 18, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhill-biopharma-announces-up-to-19-4-million-private-placement-302804327.html
RedHill Biopharma Moves to Advance Opaganib as Oral Antiviral Option for Current Ebola Outbreak
June 13, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RDHL/pressreleases/2280827/redhill-biopharma-moves-to-advance-opaganib-as-oral-antiviral-option-for-current-ebola-outbreak/
RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
June 9, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68718281-redhill-biopharma-ltd-redhill-s-opaganib-receives-fda-rare-pediatric-disease-designation-for-neuroblastoma-in-addition-to-current-orphan-drug-design-008.htm
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
June 9, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhills-opaganib-receives-fda-rare-pediatric-disease-designation-for-neuroblastoma-in-addition-to-current-orphan-drug-designation-302795146.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Eagle Pharmaceuticals stock logo

Eagle Pharmaceuticals NASDAQ:EGRX

$0.88 0.00 (0.00%)
As of 10/16/2026 03:53 PM Eastern

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Finch Therapeutics Group stock logo

Finch Therapeutics Group NASDAQ:FNCH

$7.30 0.00 (0.00%)
As of 10/16/2026

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Plus Therapeutics stock logo

Plus Therapeutics NASDAQ:PSTV

$1.70 -0.18 (-9.57%)
As of 10/16/2026

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Redhill Biopharma stock logo

Redhill Biopharma NASDAQ:RDHL

$0.50 +0.02 (+4.39%)
Closing price 10/19/2026 04:00 PM Eastern
Extended Trading
$0.48 -0.02 (-4.23%)
As of 10/19/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas